JPMorgan initiated coverage of Nuvation Bio with an overweight rating and a $13 price target, implying 101% upside from Monday’s close. The bank highlighted strong commercial adoption of IBTROZI (taletrectinib) in treating advanced ROS1+ non-small cell lung cancer. Phase 3 trial data comparing taletrectinib’s efficacy against crizotinib is expected to be released in China in 2029. All 10 analysts covering the stock recommend buying, and shares have risen 56% over the past three months.
Source: Read the original article
